Answers are grounded in this paper and cite their sources.
Background Programmed cell death (PCD) is involved in tumor progression, immune regulation, and treatment response. Most studies of lung adenocarcinoma (LUAD) have focused on single death pathways or gene-based signatures, while coordination among PCD programs remains unclear. We examined the transcriptional patterns, clinical relevance, and regulatory relationships of 20 PCD programs in LUAD. Methods Transcriptomic and clinical data from TCGA, GTEx, and five GEO cohorts were analyzed. Gene set variation analysis was used to score 20 PCD signatures, which were incorporated into 801 machine-learning prognostic models. Immune features, tumor microenvironmental states, and intercellular communication were assessed using bulk and single-cell transcriptomic data. Mendelian randomization examined genetically supported associations between PCD-related traits and LUAD susceptibility. Multiplex immunofluorescence evaluated selected disulfidptosis-related proteins in tissue samples. Virtual perturbation and DepMap analyses examined cell type-specific responses associated with SLC2A1 and SLC7A11 . Candidate compounds were prioritized by transcriptome-based drug prediction and further evaluated using molecular docking and molecular dynamics simulation. PCD regulatory networks and multilevel gene regulatory networks were reconstructed and analyzed using GLMY path homology. Results The 20-PCD model showed consistent prognostic performance across the discovery and five evaluation cohorts. Disulfidptosis was repeatedly associated with poor survival, and MR provided additional genetic evidence linking disulfidptosis-related traits to LUAD susceptibility. Low-risk tumors had higher immune and stromal scores, greater cancer-immunity cycle activity, and more extensive cell-cell communication. Single-cell and tissue analyses showed distinct expression and clinical patterns of SLC2A1 and SLC7A11 in epithelial and macrophage compartments. Virtual perturbation linked SLC2A1 - and SLC7A11 -associated changes mainly to immune and antigen-presentation pathways in macrophages and membrane-related processes in epithelial cells. Drug prediction and structural analyses identified several candidate compounds. Network analyses showed marked differences in pathway- and gene-level regulatory organization between normal and tumor tissues and between low- and high-risk groups. Conclusions Multiple PCD programs are jointly altered in LUAD and differ across clinical risk states. Disulfidptosis was consistently associated with poor prognosis and LUAD susceptibility, while SLC2A1 and SLC7A11 showed cell type-dependent features in epithelial cells and macrophages. Coordinated PCD remodeling across the analyzed patient cohorts may help explain LUAD heterogeneity and prioritize molecular features for further investigation.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: